Jeffrey H. Buchalter Joins Macrogenics Board of Directors as Chairman Rockville, MD.  September 26, 2007.  MacroGenics, Inc. announced today that Mr. Jeffrey H. Buchalter has been elected as Chairman of the company’s Board of Directors.  With more than 20 years of experience in product development

Three Independent Clinical Trials Initiated with Teplizumab Manufactured at MacroGenics

MacroGenics IND for West Nile Virus Monoclonal Antibody IS ACTIVE Phase 1 Clinical Trial to Commence in 2007 ROCKVILLE, MD.  July 9, 2007.  MacroGenics announced today that the companys investigational new drug (IND) application to the U.S. Food and Drug Administration for its monoclonal antibody

JDRF Provides MacroGenics with $2 Million in Funding for "Protégé" Trial

MacroGenics Elects Industry Leader, Dr. John Maraganore, to Board of Directors Rockville , Maryland.  October 16, 2006.   MacroGenics, Inc., a privately-held immunotherapeutics company, announced today that John Maraganore, Ph.D., President and CEO of Alnylam Pharmaceuticals, has joined the

Pivotal Trial of CD3 Monoclonal Antibody to Begin in 2006

Newly Published Data Validate CD32B as Key Target in Non-Hodgkins Lymphoma

MacroGenics receives multiple government awards totaling more than $62 million to advance infectious disease programs Rockville , Maryland, October 2, 2006  MacroGenics, Inc. announced today that the National Institute for Allergy and Infectious Diseases (NIAID), part of the National Institutes of

MacroGenics Raises $45M in Series C Financing - Company to Advance Monoclonal Antibody Clinical Programs Rockville, MD, May 17, 2006  MacroGenics, Inc., a privately-held biotechnology company developing therapeutics for autoimmune disorders, cancer, and infectious diseases, today announced that it

MacroGenics Announces Grand Opening of New cGMP Manufacturing Facility in Montgomery County, Maryland Biotech Corridor ROCKVILLE, MD.  October 19 th , 2005.  MacroGenics, Inc. today announced the grand opening of its recently completed cGMP manufacturing facility located in Rockville, Maryland.

Phase 2 Clinical Trial Set to Begin

MacroGenics Builds Senior Management Team by Adding CFO and VP of Clinical Research ROCKVILLE, MARYLAND.  June 17, 2005  MacroGenics, Inc. today announced the addition of R. Nelson Campbell and Ronald L. Wilder, M.D., Ph.D. to the companys senior management team, as well as the promotions of Ezio

MacroGenics Inc. To License Novel Monoclonal Antibody Target From OriGene Technologies, Inc. For Immediate Release Rockville, MD, October 19, 2004  ROCKVILLE, Md., OCTOBER 19 -- OriGene Technologies Inc. and MacroGenics, Inc. announced today that the companies have entered into a license agreement

MacroGenics Completes Series B Financing For Immediate Release Rockville, MD, October 15, 2004  MacroGenics, Inc., a growing biotechnology company developing antibodies and vaccines to treat cancer, autoimmune disorders, and infectious diseases, announced the completion of its Series B financing of

CONTACTS: For Neose Technologies, Inc. Robert I. Kriebel - Sr. VP & CFO (215) 315-9000 Barbara Krauter - Manager (215) 315-9000 For MacroGenics Michael Richman - Exec. VP & CFO (301) 354-0681   For Immediate Release April 26, 2004 HORSHAM, Pa. , and ROCKVILLE , Md.

CONTACTS: For Genzyme Sally Curley (investors) (617) 591-7140 Dan Quinn (media) (617) 591-5849 For MacroGenics Michael Richman (301) 354-0681   For Immediate Release October 29, 2003 CAMBRIDGE, Mass. and Rockville, Md . Genzyme Corp. (Nasdaq: GENZ) and MacroGenics, Inc.

HHS Names UTMB, Seven Others as New Regional Centers To Focus on Biodefense Research The Department of Health and Human Services (HHS) today announced that the University of Texas Medical Branch at Galveston (UTMB) is among eight institutions nationwide receiving grants totaling approximately $350

$12.6 Million in Financing Completed

MacroGenics Announces Senior Appointments Rockville, MD April 1, 2002 - MacroGenics, Inc., a biotechnology company that is developing immunotherapeutics for treating cancer and inflammatory diseases, announced two key appointments to the senior management team. Michael S.

Former MedImmune Senior Vice President joins MacroGenics; Company completes key license agreements and closure of second tranche of Series A financing, bringing total raised to $13.5MM.